CA102L
/ Holy Stone Healthcare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2023
Evaluation of the antitumor activity of ca102l, a hyaluronic acid and lenalidomide conjugate, in multiple myeloma
(AACR 2023)
- "In summary CA102L as a single agent, exhibited greater efficacy than Len in preclinical MM models, thus representing a promising potential therapeutic strategy for MM. Studies presently are ongoing to further evaluate CA102L’s preclinical profile to advance the candidate into the clinic."
Hematological Malignancies • Multiple Myeloma • Oncology • CD31 • CRBN • PECAM1
1 to 1
Of
1
Go to page
1